Please login to the form below

Not currently logged in
Email:
Password:

Gilead Sciences promotes Dr Alessandro Riva to EVP, oncology therapeutics

He's been with the firm since January, when he joined from Novartis

Gilead Sciences has promoted Dr Alessandro River from senior vice president, haematology and oncology therapeutic area head, to executive vice president, oncology therapeutics.

Dr Riva joined the biopharmaceutical group in January 2017, and his previous role saw him take responsibility in expanding Gilead’s oncology programme with the recent acquisition of Kite Pharma.

Prior to Gilead, Dr Riva served as head, global oncology development at Novartis, where he oversaw the development and worldwide regulatory approval of multiple compounds in a variety of tumour types.

John McHutchinson, executive vice president, clinical research, Gilead, said: “Alessandro’s vision and insight have helped Gilead broaden and deepen our oncology pipeline through the acquisition of Kite Pharma, and his exceptional leadership has guided the company’s broader haematology/oncology strategy.

“In his new role, I am confident that Gilead’s haematology and oncology programmes will continue to expand, as we seek to advance new therapies with the potential to transform the treatment of patients with cancer.”

20th October 2017

From: Sales

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Viseven

Viseven is a full cycle digital agency with 10 years expertise in developing content for the global pharmaceutical market delivering...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics